Evidence map›Paper›PMID 41150177›Full record

ReviewToxins2025

Onabotulinumtoxin-A for Chronic Migraine in Children and Adolescents: A Narrative Review of Current Evidence and Clinical Perspectives.

Laura Papetti, Paolo Martelletti, Massimiliano Valeriani

Abstract readReview
In one paragraph

Review in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laura PapettiDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Piazza di Sant'Onofrio 4, 00165 Rome, Italy.ORCID 0000-0002-3336-9205
Paolo MartellettiSchool of Health, Unitelma Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-6556-4128
Massimiliano ValerianiDevelopmental Neurology Unit, Bambino Gesù Children's Hospital, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Piazza di Sant'Onofrio 4, 00165 Rome, Italy.ORCID 0000-0001-6602-103X

Funding

Ministry of Health Italy Current reasearch
6 · The paper itself

Abstract

Chronic migraine (CM) in childhood and adolescence is associated with a high disease burden, including impaired quality of life, school absenteeism, and reduced daily functioning. OnabotulinumtoxinA (ONA) is approved for prophylactic treatment of CM in adults, but its use in pediatric patients remains off-label, with evidence still limited. This narrative review summarizes current data on the efficacy, safety, and tolerability of ONA in pediatric CM, drawing from randomized controlled trials, prospective cohorts, and retrospective series. In addition to summarizing efficacy and safety data, our review aims to focus on potential practical clinical implications and on discussion points and research questions that remain open.

Indexed as

Acetylcholine Release InhibitorsBotulinum Toxins, Type AMigraine DisordersNeuromuscular AgentsAdolescentChildChronic DiseaseHumansTreatment OutcomeAcetylcholine Release InhibitorsBotulinum Toxins, Type ANeuromuscular Agentsonabotulinum toxin Aadolescentschildrenchronic migraineheadachemigraineONAonabotulinumtoxin-a

Identifiers

PMID41150177
PMCPMC12567757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.